Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods.

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• Myeloid cell leukemia-1 (Mcl-1) is a key regulator of apoptosis and a frequent target in cancer therapy.
• Mcl-1 overexpression drives cancer progression and confers resistance to chemotherapy by inhibiting programmed cell death.
• Mcl-1 interacts with pro-apoptotic proteins via hydrophobic pockets in its binding groove.

Purpose of the Study:

• To discover and characterize novel small-molecule inhibitors of Mcl-1.
• To develop potent and selective Mcl-1 inhibitors for potential therapeutic applications.
• To elucidate the binding interactions of novel inhibitors with Mcl-1 through structural analysis.

Main Methods:

• Fragment-based drug discovery approaches.
• Structure-based drug design and optimization.
• X-ray crystallography to determine inhibitor-Mcl-1 complex structures.

Main Results:

• Identification of novel Mcl-1 inhibitors with low nanomolar binding affinities.
• Achieved >500-fold selectivity for Mcl-1 over Bcl-xL.
• Detailed structural insights into small-molecule binding to Mcl-1, guiding optimization.

Conclusions:

• Novel fragment-derived inhibitors effectively target Mcl-1.
• High selectivity and potency achieved through structure-based design.
• These Mcl-1 inhibitors represent promising candidates for overcoming chemotherapy resistance in cancer.